pan>)--PharmMD, the nations leader in quality Medication
Therapy Management (MTM), today announced Janet Petraroi as Chief
Financial Officer and Michael
Ansel as Chief Development Officer.
“Michael has
been a major contributor to PharmMDs exponential growth and management
team”
The new appointments for Ms. Petraroi and Mr. Ansel will advance our
objective to being the nations leader in MTM and support our business
growth strategy, says Bo
Bartholomew, CEO of PharmMD.
Janet Petraroi, CPA joins PharmMD as Chief Financial Officer. She
previously served as Principal at Professional Accounting and Management
Services and Professional Alliance for Managed Care Services. She has
over 25 years of financial and accounting experience in the health care
industry, holding senior level positions with companies such as FOCUS
Healthcare, Coventry Corporation and Equicor Health Plan. Petraroi is a
Certified Public Accountant and received her B.S. in Business
Administration from Old Dominion University.
Michael Ansel has been named Chief Development Officer at PharmMD. Ansel
had previously served as PharmMDs Vice President of Sales. In his new
role, he is responsible for driving all business development efforts for
PharmMD and managing a national team of sales executives. Michael has
been a major contributor to PharmMDs exponential growth and management
team, says Bartholomew. His appointment as Chief Development Officer
is a result of his track record of success at increasing sales for the
past few years.
About PharmMD
PharmMD is the quality leader in Medication Therapy Management
Solutions. Based in Brentwood, Tenn., PharmMD works with employers and
health plans to prevent medication related health problems through the
application of the best pharmacist and physician knowledge using their
proprietary MTM software. Founded in 2006, PharmMD improves coordination
and communication among physicians, pharmacists, payers and patients by
analyzing pharmacy and medical claims information and clinical decision
making. Because PharmMD focuses exclusively on MTM, the company is able
to analyze both aggregate and patient-specific data to identify trends
and conflicts to positively impact patient health and contain costs.
More information at: www.pharmmd.com.

Information Source: Business Wire